TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31564689

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy using purified cedar allergen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0
Study: 29692285

Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT), 40 sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 70
Study: 28734816

Group type: EXPERIMENTAL
Intervention: Portable nonmydriatic fundus camera
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard mydriatic fundus camera
Number of subjects: 211
Study: 25728339

Group type: EXPERIMENTAL
Intervention: Coach education sessions for coaches (2 sessions lasting approximately 2 hours each)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no coach education)
Number of subjects: 76
Study: 23325450

Group type: EXPERIMENTAL
Intervention: IPE 4 g/day
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: IPE 2 g/day
Number of subjects: 931

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study: 21289266

Group type: EXPERIMENTAL
Intervention: hCG 15 IU sc every other day for 10 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: hCG 60 IU sc every other day for 10 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: hCG 125 IU sc every other day for 10 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: GnRH antagonist acyline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (0 IU hCG)
Number of subjects: 23
Study: 19190344

Group type: EXPERIMENTAL
Intervention: 50 mg supplemental vitamin E (alpha‐tocopherol) per day
Number of subjects: 1833

Group type: EXPERIMENTAL
Intervention: Genetic variation in TTPA and SEC14L2
Number of subjects: 1833
Study: 16723156

Group type: EXPERIMENTAL
Intervention: High doses of intravenous methylprednisolone
Number of subjects: 32
Study: 12969098

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (EA and Sham)
Number of subjects: 45
Study: 11115208

Group type: EXPERIMENTAL
Intervention: Guideline-concordant antidepressant medication or specialty counseling
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Severity of physical problems
Number of subjects: 92
Study: 8884819

Group type: EXPERIMENTAL
Intervention: Demineralized bone powder
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 14
Study: 1528609

Group type: EXPERIMENTAL
Intervention: Low-dose antigen injection
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 5
Study: 3877291

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pethidine 50‐75 mg intramuscularly and atropine 0.6 mg intramuscularly
Number of subjects: 120
Study: 31862740

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) administered by trained paramedics
Number of subjects: 7

Group type: COMPARATOR
Intervention: Usual care (most commonly morphine)
Number of subjects: 7
Study: 29246363

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (≥100 pg/mL)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: TNF‐α (≥5.6 pg/mL)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Troponin (≥0.01 ng/mL)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Left ventricular mass
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Left atrial internal dimension
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: E/Em ratio (diastolic dysfunction)
Number of subjects: 521
Study: 27029746

Group type: EXPERIMENTAL
Intervention: Ibuprofen use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubal ligation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of ectopic pregnancy
Number of subjects: 0
Study: 25267716

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 1359

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1359
Study: 21897297

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 40
Study: 21149931

Group type: EXPERIMENTAL
Intervention: NEUMUNE (5‐androstenediol injectable suspension) administered intramuscularly at doses of 50, 100, 200 or 400 mg, either as a single injection or once daily for five consecutive days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 18057405

Group type: EXPERIMENTAL
Intervention: Caffeine supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 10
Study: 16598180

Group type: EXPERIMENTAL
Intervention: One-step conventional adhesive system (PQ1) with 35% phosphoric acid etching for 60 seconds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-etching adhesive system (Adper Prompt L Pop) applied without prior acid etching
Number of subjects: 0
Study: 12112791

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate inhalation before sleep
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11951580

Group type: EXPERIMENTAL
Intervention: Hymecromone (300 mg tablets at a dosage of 1,200 mg/day, 2 tablets midday and evening)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Hymecromone
Number of subjects: 123
Study: 9605674

Group type: COMPARATOR
Intervention: 0.0 MAC (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.6 MAC desflurane
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 8
Study: 7908864

Group type: EXPERIMENTAL
Intervention: BRL 35135 (8 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bisoprolol (5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nadolol (20 mg)
Number of subjects: 8
Study: 3048052

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Regular treatment (RT)
Number of subjects: 102
Study: 30575798

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (triglyceride dietary supplements or prescription ethyl esters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endotoxin challenge (low dose intravenous lipopolysaccharide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in Study B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endotoxin challenge
Number of subjects: 0
Study: 27939192

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus anterior plane block (SAPB) with 30 mL of 0.25% levobupivacaine followed by 5 mL/hour of 0.125% levobupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA) with a lower dose regimen activated before extubation
Number of subjects: 40
Study: 26576533

Group type: EXPERIMENTAL
Intervention: Early adjuvant radiotherapy for 6 weeks (60 Gy in 30 fractions)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 190
Study: 23545279

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (nab-P) 100 mg/m² weekly + carboplatin (C)
Number of subjects: 149

Group type: COMPARATOR
Intervention: solvent-based paclitaxel (sb-P) 200 mg/m² every 3 weeks + carboplatin (C)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: nab-P + C
Number of subjects: 149

Group type: COMPARATOR
Intervention: sb-P + C
Number of subjects: 149
Study: 21576081

Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries
Number of subjects: 168

Group type: COMPARATOR
Intervention: Immediate rFSH
Number of subjects: 168
Study: 19047840

Group type: EXPERIMENTAL
Intervention: Specially processed cereals
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nonprocessed cereals
Number of subjects: 26
Study: 16556178

Group type: EXPERIMENTAL
Intervention: Rennie alginate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gaviscon
Number of subjects: 12
Study: 14689840

Group type: EXPERIMENTAL
Intervention: NILS-Longitudinal Study of Aging (NILS-LSA)
Number of subjects: 2300
Study: 10878692

Group type: EXPERIMENTAL
Intervention: Verapamil SR 180 mg/trandolapril 2 mg (VT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Captopril 50 mg/hydrochlorothiazide 25 mg (CH)
Number of subjects: 100
Study: 9128476

Group type: EXPERIMENTAL
Intervention: Self-Management Program (cognitive-behavioural intervention)
Number of subjects: 65
Study: 1408866

Group type: EXPERIMENTAL
Intervention: Taped relaxation message
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sitting quietly (Control)
Number of subjects: 26
Study: 30107236

Group type: EXPERIMENTAL
Intervention: Fact sheet
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Motivational interviewing techniques (MI)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Web site
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Disease images
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 108
Study: 28746180

Group type: EXPERIMENTAL
Intervention: AP-lateral scout view
Number of subjects: 410

Group type: COMPARATOR
Intervention: AP scout view
Number of subjects: 410
Study: 25515174

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training (CBCT) programs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 18
Study: 22960477

Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 299

Group type: COMPARATOR
Intervention: Interdisciplinary care
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 20421519

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell therapy
Number of subjects: 0
Study: 19175893

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition during the neonatal period
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study: 17001575

Group type: EXPERIMENTAL
Intervention: Simeticone (300 mg) administered 20 min before capsule endoscopy
Number of subjects: 56

Group type: COMPARATOR
Intervention: No simeticone (control group)
Number of subjects: 56
Study: 15155295

Group type: EXPERIMENTAL
Intervention: Self-reported history of whole-body skin examination
Number of subjects: 2704

Group type: EXPERIMENTAL
Intervention: Self-reported history of whole-body skin examination in the past 12 months
Number of subjects: 2704

Group type: EXPERIMENTAL
Intervention: Demographic factors (women and younger participants)
Number of subjects: 2704

Group type: EXPERIMENTAL
Intervention: Participants with a history of melanoma
Number of subjects: 2704
Study: 11413698

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Dimenhydrinate (1 mg x kg‐1)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Droperidol (15 micrograms x kg‐1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms x kg‐1) + Dimenhydrinate (1 mg x kg‐1)
Number of subjects: 240
Study: 9404370

Group type: EXPERIMENTAL
Intervention: R-salbutamol (200-3200 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: RS-salbutamol (400-6400 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: S-salbutamol (200-3200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8215477

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of mitomycin C combined with PJ-203 (600 +/- 300 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-arterial infusion of mitomycin C alone (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of mitomycin C combined with PJ-203
Number of subjects: 60
Study: 3441275

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25-0.75 mg i.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 and 0.75 mg i.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.75 mg i.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 mg i.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28963591

Group type: EXPERIMENTAL
Intervention: Eight-week supervised exercise program (2×/week for 60 min) including endurance, resistance, and balance training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Written standard recommendations to obtain physical fitness (Control Group)
Number of subjects: 30
Study: 26763774

Group type: EXPERIMENTAL
Intervention: web-based cognitive training (eCogT) with telephone support (n=94)
Number of subjects: 157

Group type: COMPARATOR
Intervention: waitlist control (WLC) condition (n=63)
Number of subjects: 157
Study: 24943741

Group type: EXPERIMENTAL
Intervention: Intervention now group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intervention later group (waiting list)
Number of subjects: 0
Study: 22581039

Group type: EXPERIMENTAL
Intervention: Umesh's intubation detector
Number of subjects: 50
Study: 20479485

Group type: EXPERIMENTAL
Intervention: Glucose-fructose beverage (GF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glucose-only beverage (G)
Number of subjects: 9
Study: 18533979

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants with a coil spring
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonloaded implants with an annealed coil spring
Number of subjects: 20
Study: 15746784

Group type: EXPERIMENTAL
Intervention: Sharp transection group (n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Clamp crushing group (n = 41)
Number of subjects: 82
Study: 12756602

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) administered to 91 patients in the AG group
Number of subjects: 139

Group type: COMPARATOR
Intervention: Not treated with ACEI/ARB in the NON-AG group (48 patients)
Number of subjects: 139
Study: 10566921

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in normal saline (Group D)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal saline (Group NS)
Number of subjects: 119
Study: 8552700

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 0
Study: 1845926

Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1/beta 2-antagonist)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1-antagonist)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 47
Study: 6352642

Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 59

Group type: COMPARATOR
Intervention: cefazolin and tobramycin
Number of subjects: 59
Study: 31883703

Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection) at 5 seconds
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection) at 15 seconds
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (SC injection into abdomen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (SC injection into thigh)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gantenerumab (300 mg SC injection)
Number of subjects: 50
Study: 31828274

Group type: EXPERIMENTAL
Intervention: Kaplan‐Meier curve analysis for survival rate
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Cox regression analysis
Number of subjects: 279
Study: 27430594

Group type: EXPERIMENTAL
Intervention: CWI1: 15 min at 9 °C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CWI2: 15 min at 14 °C
Number of subjects: 60

Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 60
Study: 25138171

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab + Docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo + Trastuzumab + Docetaxel
Number of subjects: 808
Study: 23535882

Group type: EXPERIMENTAL
Intervention: SpineCor brace treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiotherapy only (Control)
Number of subjects: 90
Study: 21312297

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/day)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study: 19767804

Group type: EXPERIMENTAL
Intervention: Isotonic sports drink containing caffeine (6.4 g carbohydrate and 16 mg caffeine per 100 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-energy, flavour-matched placebo drink
Number of subjects: 20
Study: 17295721

Group type: EXPERIMENTAL
Intervention: Conditioned cues of monetary reward
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conditioned cues of nonreward
Number of subjects: 56
Study: 14504190

Group type: EXPERIMENTAL
Intervention: Facilitated quality improvement program to increase CRC screening
Number of subjects: 36

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 36
Study: 10803937

Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg or 480 microg subcutaneously for 2 days prior to and up to 7 days after surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Historical control group (n=27)
Number of subjects: 20
Study: 9092955

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at all three dosages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8244132

Group type: EXPERIMENTAL
Intervention: Heater probe treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 101
Study: 3533562

Group type: EXPERIMENTAL
Intervention: bufuralol (60 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: propranolol (160 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: pindolol (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: bufuralol (30-60 mg bd)
Number of subjects: 22

Group type: COMPARATOR
Intervention: propranolol (40-80 mg bd)
Number of subjects: 22
Study: 31255349

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP) - 35% protein (1.34 g/kg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard-protein diet (SP) - 18% protein (0.75 g/kg/day)
Number of subjects: 73
Study: 29916060

Group type: EXPERIMENTAL
Intervention: Individual faces associated with a high proportion of congruent trials
Number of subjects: 0
Study: 27720066

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 2453

Group type: COMPARATOR
Intervention: Other treatments
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Overall analysis (both studies)
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Amlodipine (CAMELOT)
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: BPV
Number of subjects: 2453

Group type: COMPARATOR
Intervention: Mean SBP
Number of subjects: 2453
Study: 24763706

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation in HCM patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Mid-posterior wall thickness
Number of subjects: 51

Group type: COMPARATOR
Intervention: Infero-posterior wall thickness
Number of subjects: 51
Study: 22419562

Group type: EXPERIMENTAL
Intervention: Seldinger technique
Number of subjects: 412

Group type: COMPARATOR
Intervention: Modified Seldinger technique
Number of subjects: 412
Study: 20185740

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus weight loss (10 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 25
Study: 18600034

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (daily dose = 40 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15750375

Group type: EXPERIMENTAL
Intervention: Vertigoheel (n=87)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Ginkgo biloba (n=83)
Number of subjects: 170
Study: 12214830

Group type: EXPERIMENTAL
Intervention: Retroperitoneal drainage and peritonization (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No peritonization and no drainage (Group A)
Number of subjects: 100
Study: 10379635

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.1 U x kg‐body‐weight(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Human insulin (0.1 U x kg‐body‐weight(‐1))
Number of subjects: 25
Study: 8682965

Group type: EXPERIMENTAL
Intervention: Clindamycin 1% topical solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study: 1762810

Group type: COMPARATOR
Intervention: conventional continuous stimulation (70 Hz)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: burst stimulation (90 Hz)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: high-rate frequency modulation (90 Hz to 55 Hz)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: low-rate frequency modulation (60 Hz to 20 Hz)
Number of subjects: 14
Study: 6751705

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide daily for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: 40 mg frusemide daily for 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: xipamide
Number of subjects: 15

Group type: COMPARATOR
Intervention: frusemide
Number of subjects: 15
Study: 31907019

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Physical activity plus multi-micronutrient supplementation
Number of subjects: 1320

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1320
Study: 29314376

Group type: EXPERIMENTAL
Intervention: 20 mg oral D-amphetamine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 28328713

Group type: EXPERIMENTAL
Intervention: Standard Strength Training (n = 16)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Contrast Strength Training (n = 16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (n = 12)
Number of subjects: 44